TY  - BOOK
AU  - Amr Mohammed Abd El Fattah,
AU  - Nehad Mohammed Tawfeek
AU  - Mohamed Ahmed Fateen
AU  - Ibrahim Ahmed Ibrahim Abdalgawad 
TI  - The impact of the prevalence of glutathione  S-transferase polymorphism on the response of Egyptian CML patients to tyrosine kinase inhibitor (imatinib)
U1  - 616.99419 
PY  - 2024///
KW  - Leukemia
KW  - qrmak
KW  - CML (Chronic myeloid leukemia)
KW  - Imatinib resistance
KW  - TKIs (Tyrosine kinase inhibitor )
KW  - GSTs (Glutathione transferases)
N1  - Thesis (Ph.D)-Cairo University, 2024.; Bibliography: pages 79-84.; Issued also as CD
N2  - Rationale: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm 
with an incidence of 1-2 cases per 100 000 adults. It accounts for approximately 
15% of newly diagnosed cases of leukemia in adults. Tyrosine kinase inhibitors 
(TKIs) had significantly changed the treatment landscape, improving outcomes 
for patients with CML treatment. First generation TKIs imatinib had improved 
the 8-years overall survival rate from 20 to 87%. Four generations of TKIs were 
approved and commonly used for the treatment of CML. The occurrence of 
CML is controlled by a set of factors such as exposure to environmental 
carcinogens and the ability to eliminate toxic substances. Resistance to tyrosine 
kinase inhibitors constitutes a big challenge in the treatment of patients with 
CML. This resistance could be linked to glutathione transferase activity. 
Several studies in literature studied the impact of glutathione over CML patients 
as risk of both susceptibility, treatment resistance and poor response. 
Purpose: This study aims to evaluate the presence of Glutathione transferase 
polymorphism on CML patients and the impact of glutathione s polymorphism 
on the molecular response BCR-ABL (IS %) on CML patients on the first line 
tyrosine kinase inhibitor (imatinib) 
Methodology: The study included 50 patients with chronic myeloid leukemia 
receiving tyrosine kinase inhibitor imatinib were recruited from outpatient 
hematology clinic at kasr El Einy hospital and followed over the period from 
October 2021 to October 2023. The patients were investigated for routine 
laboratory investigations including complete blood picture, liver functions, 
renal functions, molecular BCR-ABL (IS %) and glutathione s polymorphism 
Results: The study results show correlation between molecular response BCR-
ABL (IS %) of different groups of the study and severity of anemic 
manifestations with statistically significant difference of p value 0.023. The 
results of the study show no correlation between Glutathione S polymorphism 
and molecular response of CML cases among study group as no statistically 
significance difference with p value 0.94 so the study shows no impact of the 
GSP1 on the molecular response of the patients; تهدف دراستنا إلى تقييم انتشار و تأثير تعدد أشكال الجلوتاثيون على الاستجابة الجزيئية لدى المرضى المصريين بسرطان الدم الميلودي المزمن للجيل لأول من مثبطات التيروزين كيناز (ايماتينيب).
وجدت الدراسة وجود علاقة ذات دلالة إحصائية بين الاستجابة الجزيئية و حدة أعراض   فقر الدم بين المجموعات المختلفة حيث وجدنا تحسن في أعراض فقر الدم مع تحسن الاستجابة الجزيئية مع عدم وجود تأثير لتعدد أشكال الجلوتاثيون S على الاستجابة الجزيئية في حالات سرطان الدم النخاعي المزمن على إيماتينيب
ER  -